AIxCrypto Holdings Inc (NASDAQ: AIXC) is a development-stage digital asset and AI infrastructure company pursuing what it calls a Dual Flywheel strategy organized around two pillars: real-world asset tokenization (RWA) and Embodied AI (EAI) infrastructure. The company has not generated material revenue from these initiatives as of December 31, 2025. AIXC holds a concentrated basket of digital assets as part of its treasury and investment activities and maintains an internally developed AI Blockchain platform used for digital asset portfolio monitoring and analytics. In February 2026, the board discontinued development of the BesTrade trading platform and the C10 portfolio management tools, citing insufficient scale, regulatory profile, and margin characteristics. The company also retains a therapeutics program, previously conducted under the Qualigen brand, including the drug candidate QN-302, for which it is evaluating strategic options including licensing or sale. AIXC incurred a net loss of $16.9 million for the year ended December 31, 2025 and has a history of negative cash flows from operations.

Revenue model

AIXC has not generated material revenue from its digital asset or software initiatives as of December 31, 2025 (per the 10-K filed 2026-03-30). The company has funded operations through private placements of convertible preferred stock and convertible notes, including a $41 million subscription agreement entered September 19, 2025 and a $4.5 million Series A-3 Preferred Stock offering closed July 28, 2025.

Products and services

Active initiatives (as of the 10-K filed 2026-03-30): RWA tokenization infrastructure and Embodied AI (EAI) enterprise and institutional platform (both in development). Discontinued in February 2026: BesTrade trading platform and C10 digital asset portfolio management tools. Retained but under strategic review: QN-302 drug candidate (G-quadruplex stabilizer) developed in collaboration with the University of Louisville (UofL) and University College London (UCL), with Phase 1a clinical trial work previously conducted through contract research organizations.

Customers and end markets

Target end markets described as enterprise and institutional investors in AI infrastructure and programmable technology. No revenue-generating customer relationships disclosed in the filing excerpts. Investor base includes accredited investors participating in private placements.

Value-chain role

AIXC operates as an infrastructure developer in the digital asset and AI space, with no internal research and development facilities. Development of RWA and EAI platforms is handled internally. Drug candidate development was historically conducted through university licensing and sponsored research agreements with UofL and UCL, and through contracted CROs for clinical trials.

Source: SEC 10-K, filed 2026-03-30

Industry: Finance Services Peers: Bone Biologics Corp Allarity Therapeutics Inc American CryoStem Corp Protagenic Therapeutics Inc Plus Therapeutics Inc CervoMed Inc Skye Bioscience Inc ProtoKinetix Inc